Dars - aspartyl-tRNA synthetase Gene

Also Known as Dars1; 5730439G15Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 226414

Summary

Predicted to enable RNA binding activity and aspartate-tRNA Ligase activity. Predicted to be involved in aspartyl-tRNA aminoacylation. Predicted to act upstream of or within translation. Located in cytoplasm and synapse. Part of Aminoacyl-tRNA Synthetase multienzyme complex. Is expressed in several structures, including alimentary system; brain; genitourinary system; respiratory system; and sensory organ. Orthologous to human DARS1 (aspartyl-tRNA synthetase 1). [provided by Alliance of Genome Resources, Apr 2022]

Dars Products (2)

mRNA Protein Name
NM_145507.2 NP_663482.2 aspartate--tRNA ligase, cytoplasmic isoform 2
NM_177445.5 NP_803228.2 aspartate--tRNA ligase, cytoplasmic isoform 1

Gene Ontology

  • Cellular Component
Cellular Component GO Annotation Evidence References Source
part of aminoacyl-tRNA synthetase multienzyme complex IDA
IDA: Inferred from direct assay
12060739 MGI
located in cytoplasm IDA
IDA: Inferred from direct assay
27816769 MGI
located in synapse IDA
IDA: Inferred from direct assay
27816769 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

aspartate--tRNA ligase, cytoplasmic

  • aspRS

  • aspartyl-tRNA synthetase, cytoplasmic

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-10122 Silodosin Antagonist 99.89% Yes

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-101299A Dihydrexidine Agonist / Phase 1
Inhibitory Antibodies (3)
Cat. No. Product Name Effect
Purity Phase
HY-P99542 Tusamitamab ravtansine Inhibitor 99.04% Phase 3
HY-141599 Camidanlumab tesirine Inhibitor / Phase 2
HY-P99829 Cofetuzumab pelidotin Inhibitor 99.18% Phase 1

Pre-clinical Phase

Bioactive Molecules (33)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-164152A ADC Control Human IgG1-Deruxtecan (DAR 8) Inhibitor 99.32% Unkown
HY-145448 MC-VC-PABC-amide-PEG1-CH2-CC-885 99.93% Unkown
HY-101299B Dihydrexidine hydrochloride Agonist 98.89% Unkown
HY-100554 BMY 7378 99.92% Unkown
HY-163099 P5(PEG24)-VC-PAB-Exatecan 99.74% Unkown
HY-101300 Cirazoline hydrochloride Agonist 99.56% Unkown
HY-185280 Mocertatug rezetecan (DAR6) Inhibitor / Unkown
HY-175888 APL-1082 95.58% Unkown
HY-RS03533 DARS2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-101299 (+)-Dihydrexidine hydrochloride Agonist / Unkown
HY-136884 DAR-4M 98.9% Unkown
HY-161901 BC-1293 Inhibitor 98.40% Unkown
HY-175504 MLS6357 Antagonist 99.57% Unkown
HY-RS03532 DARS1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-185794 ADC Control Human IgG1 drozuntecan (DAR 6) / Unkown
HY-116982 BMY 7378 free base / Unkown
HY-118260 Phendioxan / Unkown
HY-138298B Trastuzumab deruxtecan (DAR2) Inhibitor / Unkown
HY-138298C Trastuzumab deruxtecan (DAR4) Inhibitor / Unkown
HY-138298D Trastuzumab deruxtecan (DAR6) Inhibitor / Unkown
HY-148252 ADRA1D receptor antagonist 1 free base Antagonist / Unkown
HY-156299 NMS-P945 / Unkown
HY-175669 ANO1-IN-5 Inhibitor / Unkown
HY-185773 Farletuzumab-LNK4-S (DAR8) / Unkown
HY-185773A Farletuzumab-LNK4-S (DAR4) Inhibitor / Unkown
HY-185774 ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR8) / Unkown
HY-185774A ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR4) / Unkown
HY-10122S Silodosin-d4 Antagonist / Unkown
HY-185830 ADC Control Human IgG1-vcMMAE (DAR8) Inhibitor / Unkown
HY-RS20900 Dars1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS21545 Dars2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS27417 Dars1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS28063 Dars2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (2)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-164153 ADC Control Human IgG1-vcMMAE (DAR4, solution) Inhibitor 98.08% Unkown
HY-164152 ADC Control Human IgG1-Deruxtecan (DAR 4) Inhibitor 95.61% Unkown